open access

Vol 12, No 5 (2011): Practical Diabetology
Review articles (submitted)
Published online: 2011-12-29
Get Citation

Linagliptin — a novel dipeptidyl peptidase-IV inhibitor

Władysław Grzeszczak
Diabetologia Praktyczna 2011;12(5):161-169.

open access

Vol 12, No 5 (2011): Practical Diabetology
Review articles (submitted)
Published online: 2011-12-29

Abstract

The diabetes and its complications is one of the five most frequent causes of deaths in the developed countries. So far applied therapeutic proceedings of type 2 diabetic subjects weren’t truly effective. To the purpose of the improvement the results of the treatment one should intensify current therapeutic proceedings or/and enter new groups of drugs into the treatment. One of new groups of drugs released on the market in the last period are being associated with much hope are gliptin — dipeptidyl peptidase- IV inhibitors (DPP-IV). Linagliptin is a new DPP-IV inhibitor. Authors demonstrated, that linagliptin assures meaning statistically and essential clinically effectiveness in all therapeutic outlines at present applied, so like of the monotherapy, supply with metformin, with metformin and sulphonylurea as well as initial association with pioglitazon. Improvement in the control of the blood glucose level as a result of the treatment linagliptin HbA1c, FGP and PPG values, meaning beneficial changes and the improvement in parameters of functioning of beta cells observed. Risk of side effects, particularly a risk of the appearance of the hypoglycemia is similar like applying in placebo group. (Diabet. Prakt. 2011; 12, 5: 161–169)

Abstract

The diabetes and its complications is one of the five most frequent causes of deaths in the developed countries. So far applied therapeutic proceedings of type 2 diabetic subjects weren’t truly effective. To the purpose of the improvement the results of the treatment one should intensify current therapeutic proceedings or/and enter new groups of drugs into the treatment. One of new groups of drugs released on the market in the last period are being associated with much hope are gliptin — dipeptidyl peptidase- IV inhibitors (DPP-IV). Linagliptin is a new DPP-IV inhibitor. Authors demonstrated, that linagliptin assures meaning statistically and essential clinically effectiveness in all therapeutic outlines at present applied, so like of the monotherapy, supply with metformin, with metformin and sulphonylurea as well as initial association with pioglitazon. Improvement in the control of the blood glucose level as a result of the treatment linagliptin HbA1c, FGP and PPG values, meaning beneficial changes and the improvement in parameters of functioning of beta cells observed. Risk of side effects, particularly a risk of the appearance of the hypoglycemia is similar like applying in placebo group. (Diabet. Prakt. 2011; 12, 5: 161–169)
Get Citation

Keywords

type 2 diabetes; linagliptin; structure; mechanism of action; application; side effects

About this article
Title

Linagliptin — a novel dipeptidyl peptidase-IV inhibitor

Journal

Clinical Diabetology

Issue

Vol 12, No 5 (2011): Practical Diabetology

Pages

161-169

Published online

2011-12-29

Bibliographic record

Diabetologia Praktyczna 2011;12(5):161-169.

Keywords

type 2 diabetes
linagliptin
structure
mechanism of action
application
side effects

Authors

Władysław Grzeszczak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl